company mission
Very little changed. Across 2021, 2022, and early 2023, the mission stayed the same: extend human lifespan by researching, financing, and commercializing longevity therapeutics, and do it in an open, democratic way. That is not a pivot. It is the same claim with light copy-editing. The only real shift is emphasis. The 2021 and 2022 versions read like a straight institutional purpose statement. The 2023 version adds a belief layer: human lifespan can be extended through longevity therapeutics. Same destination, slightly more ideological framing. The operational core did not move. Evidence is thin because all three entries come from archived versions of the same governance site, and all are about VitaDAO while the subject here is listed as Fission Pharma. That mismatch matters. Based on the text provided, the mission narrative is stable and the divergence is minimal, but the attribution to Fission Pharma is not proved by these sources.